VBIV - VBIワクチン (VBI Vaccines Inc.)

VBIVのニュース

   Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday  2021/06/29 20:14:01 The Motley Fool
Investors almost seemed ready to take profits once shares hit their highest level since February.
   Conference data for June 23, 2021: EASL  2021/06/29 19:45:00 BioWorld
Data presented at The International Liver Congress The Annual Meeting of the European Association for the Study of the Liver, including: Brii Biosciences, VBI Vaccines.
   VBI Vaccines Announces Positive Phase 1 Data For EVLP Vaccine Candidate Against COVID-19; Stock Up  2021/06/29 12:15:34 Business Insider Markets
(RTTNews) - VBI Vaccines Inc. (VBIV) announced positive Phase 1 data from its Phase 1/2 trial of the first of its enveloped virus-like particle or eVLP COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age. In Tuesday pre-market trade, VBIV was trading at $4.33 up $0.32 or 7.98%. The company noted that the 5µg dose
   VBI Vaccines shares rise on data from early-stage COVID-19 vaccine study  2021/06/29 11:58:56 Seeking Alpha
   Samenvatting: Brii Biosciences en VBI-vaccins presenteren positieve gegevens van voltooide fase 1b/2a-studie over BRII-179 (VBI-2601) bij patiënten met chronische hepatitis B op het International Liver Congress 2021  2021/06/23 16:27:00 Business Wire
DURHAM, N.C. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio) en VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), kondigden vandaag de definitieve resultaten aan van een Fase 1b/2a studie met BRII-179 (VBI-2601), een nieuwe recombinante immunotherapeutische kandidaat op basis van eiwitten, bij patiënten met chronische hepatitis B-virus (HBV) infectie. De gegevens van de studie, die de veiligheid, antivirale activiteit en immunogeniciteit van BRII-179 (VBI-2601) alleen of ge
   Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday  2021/06/29 20:14:01 The Motley Fool
Investors almost seemed ready to take profits once shares hit their highest level since February.
   Conference data for June 23, 2021: EASL  2021/06/29 19:45:00 BioWorld
Data presented at The International Liver Congress The Annual Meeting of the European Association for the Study of the Liver, including: Brii Biosciences, VBI Vaccines.
   VBI Vaccines Announces Positive Phase 1 Data For EVLP Vaccine Candidate Against COVID-19; Stock Up  2021/06/29 12:15:34 Business Insider Markets
(RTTNews) - VBI Vaccines Inc. (VBIV) announced positive Phase 1 data from its Phase 1/2 trial of the first of its enveloped virus-like particle or eVLP COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age. In Tuesday pre-market trade, VBIV was trading at $4.33 up $0.32 or 7.98%. The company noted that the 5µg dose
   VBI Vaccines shares rise on data from early-stage COVID-19 vaccine study  2021/06/29 11:58:56 Seeking Alpha
   Samenvatting: Brii Biosciences en VBI-vaccins presenteren positieve gegevens van voltooide fase 1b/2a-studie over BRII-179 (VBI-2601) bij patiënten met chronische hepatitis B op het International Liver Congress 2021  2021/06/23 16:27:00 Business Wire
DURHAM, N.C. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio) en VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), kondigden vandaag de definitieve resultaten aan van een Fase 1b/2a studie met BRII-179 (VBI-2601), een nieuwe recombinante immunotherapeutische kandidaat op basis van eiwitten, bij patiënten met chronische hepatitis B-virus (HBV) infectie. De gegevens van de studie, die de veiligheid, antivirale activiteit en immunogeniciteit van BRII-179 (VBI-2601) alleen of ge
   VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases  2021/05/12 14:15:56 Benzinga
VBI Vaccines Inc (NASDAQ: VBIV ) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate in adults were published in The Lancet Infectious Diseases. The study was designed to compare the immunogenicity and safety of 10 µg of VBI's 3-antigen vaccine candidate to 20 µg of the single-antigen HBV vaccine, Engerix-B, made by GlaxoSmithKline Plc (NYSE: Full story available on Benzinga.com
   Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study  2021/04/21 12:50:00 Benzinga
Privately-held Brii Biosciences , Vir Biotechnology Inc (NASDAQ: VIR ), and VBI Vaccines Inc (NASDAQ: VBIV ) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination with BRII-179 (VBI-2601) for the treatment of chronic HBV infection. The open-label study is … Full story available on Benzinga.com
   Samenvatting: CEPI- en VBI-vaccins werken samen om vaccinkandidaten te bevorderen tegen COVID-19-varianten  2021/03/10 16:02:00 Business Wire
OSLO, Norway & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CEPI, de Coalition voor Epidemic Preparedness Innovations, en VBI Vaccines Inc. (Nasdaq: VBIV), hebben vandaag een samenwerking aangekondigd om VBI’s omhulde virusachtige deeltjes (eVLP) vaccinkandidaten te ontwikkelen tegen SARS-CoV-2-varianten, waaronder de B.1.351-variant, ook bekend als 501Y.V2, voor het eerst geïdentificeerd in Zuid-Afrika. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshul
   VBI Vaccines (NASDAQ:VBIV) Announces Quarterly Earnings Results  2021/03/04 12:26:42 Transcript Daily
VBI Vaccines (NASDAQ:VBIV) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06), MarketWatch Earnings reports. VBI Vaccines had a negative return on equity of 36.69% and a negative net margin of 2,837.73%. NASDAQ:VBIV opened at $3.08 on Thursday. The […]
   VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021  2021/03/02 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the fourth quarter and twelve months ended December 31, 2020. The Company also provided a corporate update and its outlook for 2021. Annual Note from Jeff Baxter, President and CEO: “2020 was, unfortunately, a historic year, marked by unprecedented disruption, with severe

calendar